NCT03012334View on ClinicalTrials.gov

The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions
Migraine
Interventions
DRUG

Lasmiditan

Dose is based on treatment sequence in 5-way crossover

DRUG

Alprazolam

Active comparator based on treatment sequence in 5-way crossover

OTHER

Placebo

Placebo comparator based on treatment sequence in 5-way crossover

Trial Locations (1)

H3P3P1

Algorithme Pharma, Mount Royal

Sponsors
All Listed Sponsors
collaborator

Algorithme Pharma Inc

INDUSTRY

collaborator

Cognitive Research Corporation

INDUSTRY

collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY